Amarin Corp Plcuk (AMRN) Interest & Investment Income (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Interest & Investment Income of $2.4 million for Q1 2026, down 15.63% YoY from $2.9 million in Q1 2025, and down 5.94% sequentially from $2.6 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Interest & Investment Income (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Interest & Investment Income across 17 years of filings, most recently posting $2.4 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 15.63% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $10.4 million (down 19.31% YoY), while the FY2025 annual figure was $10.9 million, down 19.03% from the prior year.
- Interest & Investment Income fell to $2.4 million in Q1 2026, from $2.6 million in the prior quarter.
- Over the last five years, Interest & Investment Income for AMRN reached as high as $3.4 million in Q4 2023 and fell as low as $203000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $2.8 million (2025), against an average of $2.4 million.
- Annual changes were most pronounced in 2022 — Interest & Investment Income slumped 56.9% — and 2023, when it soared 994.09%.
- A 5-year view of Interest & Investment Income shows it stood at $1.6 million in 2022, then jumped by 117.05% to $3.4 million in 2023, then retreated by 1.46% to $3.4 million in 2024, then dropped by 23.67% to $2.6 million in 2025, then declined by 5.94% to $2.4 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $2.4 million, $2.6 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 229.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -645.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 73.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 2.78 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.38 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.58 Mn |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 288,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 301,000.00 |
| Sep 30, 2021 | 163,000.00 |
| Jun 30, 2021 | 285,000.00 |